uso 20408

A Phase Ill, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor - Positive, Her2‑Negative Early Breast Cancer (Go42784)

Disease Types: Breast Cancer Research

Eligibility Requirements:

- ER+, HER2 – Breast Cancer, must have under definitive surgery for disease and completed adjuvant therapy prior to randomization 

- No:  active cardiac disease or history of cardiac dysfunction, metastatic breast cancer; clinically significant liver disease or active hepatitis B or C; coagulopathy or thromboembolism; inability to swallow or absorb oral medication

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)